- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Unmet Needs in Treatment of MDD
Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).
EP: 1.Unmet Needs in Treatment of MDD
EP: 2.MDD Treatment Landscape
EP: 3.Potential Consequences of Recurrent or Poorly Controlled MDD
EP: 4.Burden of Treatment Failure in MDD
EP: 5.Importance of Early Effective Treatment of MDD
EP: 6.Evaluating MDD Treatment Attributes
EP: 7.Considerations for Newly Launched MDD Treatments
EP: 8.Healthcare Disparities Within Major Depressive Disorder
EP: 9.MDD Treatment Disparities Across Patient Populations
EP: 10.Social Determinants of Health in MDD
EP: 11.Impact of COVID-19 on Demand for Mental Health Services
EP: 12.Health Care Disparities Within Major Depressive Disorder (MDD)
EP: 13.MDD Treatment Disparities Across Patient Populations: Part 2
EP: 14.Social Determinants of Health in MDD: Part 2
EP: 15.Population Health Approach in MDD
EP: 16.Factors Affecting MDD Treatment Adherence
EP: 17.Supporting Adherence for Patients with MDD
EP: 18.Aligning MDD Treatment Goals for Payers and Patients
EP: 19.The Impact of Early Effective Treatment in MDD
EP: 20.Key Contributors to Long-term Outcomes for Patients With MDD
Michael Rothrock, MBA, MHA: When we talk about the biggest unmet needs among the treatment options for MDD [major depressive disorder], a few things stick out. We’re looking for new mechanisms of action and, more important, quicker onsets of action. We want patients to get a high response in the shortest time possible. Even though most drugs are generic and very inexpensive, they could take up to 8 weeks to show benefit. We’re looking for higher response rates, a shorter onset of action, and a longer durability of benefit, with improved tolerability and adverse effects.
H. Eric Cannon, PharmD, FAMCP: The reality is that patients are waiting. With COVID-19, we had all kinds of delays, so we need to have treatments that quickly start to show some benefit. The full benefit won’t happen immediately, but patients are in a bad way right now. The faster we can get the onset, the easier it is for us to identify appropriate treatments. Those are the 2 big unmet needs.
Transcript edited for clarity.
Real-World Data Show Bevacizumab Benefits Only High-Risk Patients With Epithelial Ovarian Cancer
May 13th 2025In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with epithelial ovarian cancer and high-risk prognostic factors.
Read More
Global Analysis Sheds Light on Women’s Cancer Trends
May 11th 2025As National Women’s Health Week approaches, new global data highlighting projected rises in breast and ovarian cancer through 2050 is prompting renewed calls for gender-specific prevention strategies that address evolving health risks for women.
Read More
